Diagnosis of SARS-CoV-2 infection: preliminary results of six serology tests

Dijagnostika SARS-CoV-2 infekcije: preliminarni rezultati šest seroloških testova

Tatjana Vilibić-Čavlek1,2*, Vladimir Stevanović3*, Irena Tabain1, Ljiljana Perić1,5, Dario Sabadi4,5, Željka Hruškar1, Ljiljana Milašinčić1, Ljiljana Antolašić1, Maja Bogdanić2, Vladimir Savić6, Ljubo Barbić3

1 authors with equal contribution
1 Department of Virology, Croatian Institute of Public Health, Zagreb, Croatia
2 School of Medicine, University of Zagreb, Zagreb, Croatia
3 Department of Microbiology and Infectious Diseases with Clinic, Faculty of Veterinary Medicine University of Zagreb, Zagreb, Croatia
4 Clinic for Infectious Diseases, Clinical Hospital Center Osijek, Osijek, Croatia
5 Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
6 Poultry Center, Croatian Veterinary Institute, Zagreb, Croatia

Abstract

The most important use of serology in the COVID-19 diagnostics is for determination of the extent of disease in the population. However, immunoassays could represent an additional diagnostic method, especially in patients with exposure history and clinical symptoms compatible with COVID-19 who failed to be confirmed by RT-PCR. We analyzed the preliminary results of six serology tests for the diagnosis of SARS-CoV-2. Three point-of-care lateral flow chromatographic immunoassays (POC): ACRO, AMP and ENCODE and three enzyme immunoassays (ELISA): DiaPro, Vircell and Euroimmun were used. A total of 15 serum samples from COVID-19 patients and 15 serum samples from asymptomatic persons were tested. Time of sampling for COVID-19 patients was 4 – 10 days (N=4), 11 – 19 days (N=6) and 20 – 34 days (N=5) after disease onset. Initially reactive results were confirmed using a virus neutralization test (VNT). In COVID-19 patients (N=15), IgM/IgA positive detection rates were 9/60.0% (ACRO), 11/73.3% (AMP, ENCODE, Euroimmun), 12/80.0% (DiaPro) and 13/86.6% (Vircell). Overall IgG detection rates were 10/66.6% (AMP, Euroimmun) and 11/73.3% (other tests). According to the sampling time, positive detection rates were as follows: a) days 4 – 10: 1/25.0% and 2/50.0% (IgM/IgA and IgG); b) days 11 – 19: 4/66.6%-6/100% (IgM/IgA), 4/66.6% and 5/83.3% (IgG); c) days 20 – 34: 4/80.0% and 5/100% (IgM/IgA), 5/100% (IgG). One asymptomatic participant tested IgM/IgA positive using ACRO, DiaPro and Vircell was confirmed seropositive using a VNT. In a group of asymptomatic persons detected seronegative using a VNT (N=14), IgM/IgA negative detection rates were 12/85.7% (ACRO), 13/92.8% (DiaPro, Vircell) and 14/100% (AMP, ENCODE, Euroimmun). IgG negative detection rates were 13/92.8% (ACRO) and 14/100% (other tests). ELISA tests showed a higher overall IgM/IgA sensitivity compared to POC tests in patients with COVID-19, while the IgG sensitivity was similar in both POC and ELISA.

Keywords:
COVID-19
SARS-CoV-2
serology
point-of-care tests
ELISA

Sažetak

Najznačajnija primjena seroloških testova u dijagnostici COVID-19 je u svrhu procjene proširenosti bolesti u populaciji. Međutim, imunotestovi mogu poslužiti kao dodatni dijagnostički postupak, posebice kod bolesnika s podatkom o izloženosti COVID-19 i prisutnim kliničkim simptomima, kod kojih je rezultat RT-PCR testa bio negativan. U ovome smo radu analizirali preliminarni rezultate šest seroloških testova za dijagnostiku SARS-CoV-2. Korištena su tri ‘point-of-care’ imunokromatografska testa (POC): ACRO, AMP i ENCODE te tri imunoenzimska testa (ELISA): DiaPro, Vircell i Euroimmun. Testirano je ukupno 15 seruma bolesnika s COVID-19 infekcijom i 15 uzorka seruma asimptomatskih osoba. Vrijeme uzorkovanja kod bolesnika s COVID-19 iznosilo je 4 – 10 dana (N=4), 11 – 19 dana (N=6) te 20 – 34 dana (N=5) od početka bolesti. Svi su početno reaktivni rezultati potvrđeni testom neutralizacije virusa (VNT). Kod bolesnika s COVID-19 (N=15), učestalost detekcije IgM/IgA protutijela iznosila je 9/60.0% (ACRO), 11/73.3% (AMP, ENCODE, Euroimmun), 12/80.0% (DiaPro) te 13/86.6% (Vircell). Učestalost detekcije IgG protutijela iznosila je 10/66.6% (AMP, Euroimmun) te 11/73.3% (ostali testovi). Ovisno o vremenu uzorkovanja, učestalost detekcije protutijela iznosila je: a) 4 – 10 dana: 1/25.0% i 2/50.0% (IgM/IgA i IgG); b) 11 – 19. dana: 4/66.6%-6/100% (IgM/IgA), 4/66.6% i 5/83.3% (IgG); c) 20 – 34. dana: 4/80.0% i 5/100%.
Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in December 2019 in Wuhan, China. Due to its rapid global transmission, the World Health Organization (WHO) declared a pandemic in May 2020. Globally, 30,905,162 cases and 958,703 deaths due to coronavirus disease (COVID-19) in 216 countries were reported to WHO as of September 21, 2020[1]. Person-to-person SARS-CoV-2 transmission is thought to occur among close contacts mainly via respiratory droplets[2]. However, other routes of transmission including feco-oral[3] and through eye secretions are also suggested[4]. Clinical spectrum of COVID-19 varies from asymptomatic infection to severe and fatal pneumonia[5]. SARS-CoV-2 diagnosis is based on detection of viral RNA in respiratory specimens using a reverse-transcriptase polymerase chain reaction (RT-PCR), while serology is useful for determining the extent of disease in the population. However, immunoassays could represent an additional diagnostic method that could provide information on active/recent SARS-CoV-2 infection, especially in patients with exposure history and clinical symptoms compatible with COVID-19 who failed to be confirmed by RT-PCR[6,7]. Different serology tests are commercially available, including point-of-care lateral flow chromatographic immunoassays (POC) and enzyme immunoassays (ELISA)[8]. However, cross-reactivity to other coronaviruses can be challenging.

The aim of this study was to analyse the preliminary results of six serology tests for SARS-CoV-2 diagnosis.

Materials and Methods

A total of 30 serum samples collected from patients with RT-PCR confirmed COVID-19 (N=15) and asymptomatic persons with negative SARS-CoV-2 RT-PCR test (N=15) were tested for the presence of SARS-CoV-2 IgG and IgM and/or IgA antibodies by using six different commercial serology tests: three POC and three ELISA tests (Table 1). Time of sampling for COVID-19 patients was 4 – 10 days (N=4), 11-19 days (N=6) and 20 – 34 days (N=5) after disease onset. The results of ELISA were calculated according to the manufacturer’s recommendation and expressed as follows: a) sample/calibration ratio; S/Co (DiaPro), b) antibody index; AI (Vircell), c) absorbance ratio (Euroimmun).

Table 1. Serology tests used for SARS-CoV-2 antibody detection

| Test                        | Manufacturer                          | Antigen          | Reference values                                                                 |
|-----------------------------|---------------------------------------|------------------|----------------------------------------------------------------------------------|
| Point-of-care lateral chromatic immunoassay |                                       |                  |                                                                                  |
| ACRO 2019-nCoV IgG/IgM Rapid Test Casette | Acro Biotech, Rancho Cucamonga, CA, USA | NA               |                                                                                  |
| AMP Rapid Test SARS-CoV-2 IgG/IgM | AMEDA Labordiagnostik, Graz, Austria | NA               |                                                                                  |
| ENCODE COVID-19 IgM/IgG     | Zuhai Encode Medical Engeneering, Zuhai, China | NA               |                                                                                  |
| Enzyme immunoassay          |                                       |                  |                                                                                  |
| COVID-19 IgM; IgA; IgG      | DiaPro, Sesto San Giovanni, Italy     | N, S             | IgM/IgG/IgA (S/Co) <0.9 negative; 0.9-1.1 equivocal; >1.1 positive               |
| Covid-19 ELISA IgM+IgA; IgG | Vircell, Granada, Spain               | N, S             | IgM/IgA (AI) <6 negative; 6-8 borderline; >8 positive                             |
| Anti-SARS-CoV-2 ELISA IgA; IgG | Euroimmun, Lübeck, Germany            | S                | IgA/IgG (absorbance ratio) <0.8 negative; 0.8-1.1 borderline; >1.1 positive     |

N = nucleocapsid; S = spike protein; NA = data not available
All initially reactive IgM, IgG or IgA samples were confirmed by using a virus neutralization test (VNT). SARS-CoV-2 HR1/8933 strain, isolated from the nasopharyngeal swab of COVID-19 patient on Vero E6 cells, was used for VNT. Maximum cytopathic effect was visible on the 4th day after inoculation and the virus replication was confirmed by RT-PCR. Prior to VNT, virus was titrated by 50% TCID₅₀ (TCID₅₀) by using Vero cells and the titer was determined using the Reed and Muench formula. Heat inactivated serum samples (56°C/30 min) were tested in duplicate in 96-well plates. Two-fold serum dilutions starting from 1:2 were prepared and mixed with the equal volume (25 µl) containing 100 TCID₅₀ of the virus. After 1 h of incubation at 37°C in CO₂ incubator, 50 µl of Vero E6 cells in a concentration of 2x10⁵ cells/ml, was added to each well and incubated for four days. The antibody titer was defined as the reciprocal value of the highest serum dilution that showed 100% neutralization in at least half of the infected wells. Titer of >8 was considered positive⁹.

The study was approved by the Ethics Committee of the Croatian Institute of Public Health.

**Results**

The serology results are presented in Figures 1 – 2 and Table 2. In a group of COVID-19 patients, IgM and/or IgA antibodies were detected in 9/60.0% (ACRO), 11/73.3% (AMP), 12/80.0% (ENCODE), 12/80.0% (DiaPro), 13/86.6% (Vircell) and 11/73.3% (Euroimmun) serum samples. The overall detection rates of IgG antibodies were 11/73.3% (ACRO), 10/66.6% (AMP), 11/73.3% (ENCODE), 11/73.3% (DiaPro), 11/73.3% (Vircell) and 10/66.6% (Euroimmun) (Figure 1).

**Table 2. IgM/IgA and IgG SARS-CoV-2 detection rate in COVID-19 patients according to the sampling time**

| Day* | N  | ACRO IgM (%) | ACRO IgG (%) | AMP IgM (%) | AMP IgG (%) | ENCODE IgM (%) | ENCODE IgG (%) | DiaPro IgM (%) | DiaPro IgG (%) | Vircell IgM (%) | Vircell IgG (%) | Euroimmun IgM (%) | Euroimmun IgG (%) | Euroimmun IgA (%) |
|------|----|-------------|-------------|------------|------------|----------------|----------------|----------------|----------------|----------------|----------------|------------------|----------------|----------------|
| 4-10 | 4  | 1 (25.0%)   | 1 (25.0%)   | 1 (25.0%)  | 1 (25.0%)  | 2 (50.0%)      | 2 (50.0%)      | 2 (50.0%)      | 2 (50.0%)      | 2 (50.0%)      | 2 (50.0%)      | 2 (50.0%)         | 1 (25.0%)        | 1 (25.0%)       |
| 11-19| 6  | 4 (66.6%)   | 5 (83.3%)   | 5 (83.3%)  | 4 (66.6%)  | 4 (66.6%)      | 5 (83.3%)      | 5 (83.3%)      | 4 (66.6%)      | 5 (83.3%)      | 6 (100%)       | 4 (66.6%)         | 4 (66.6%)        | 5 (83.3%)       |
| 20-34| 5  | 4 (80.0%)   | 5 (100%)    | 5 (100%)   | 5 (100%)   | 5 (100%)       | 5 (100%)       | 5 (100%)       | 5 (100%)       | 5 (100%)       | 5 (100%)       | 5 (100%)         |                 |                |

*days after disease onset

**Figure 1. IgM/IgA and IgG SARS-CoV-2 positive detection rate in COVID-19 patients (N=15)**

Slika 1. Učestalost pozitivne detekcije IgM/IgA i IgG protutijela u bolesnika s COVID-19 (N=15)

*simultaneous IgM/IgA detection/istodobna detekcija IgM/IgA
In a group of asymptomatic persons, one participant tested IgM/IgA positive using ACRO, DiaPro and Vircell was confirmed seropositive using a VNT. AMP and ENCODE tests showed a false negative IgM result. Titers of neutralizing antibodies were 8 (asymptomatic person) and 32 – 256 (patients with RT-PCR confirmed COVID-19). In the other 14 samples confirmed negative using a VNT, IgM and/or IgA negative detection rates were 12/85.7% (ACRO), 13/92.8% (DiaPro and Vircell) and 14/100% (AMP, ENCODE, Euroimmun). IgG negative detection rates were 13/92.8% (ACRO) and 14/100% (AMP, ENCODE, DiaPro, Vircell, Euroimmum) (figure 2).

IgM/IgA detection rates in COVID patients according to sampling time after disease onset varied from 1/25.0% to 2/50.0% (days 4 – 10), 4/66.6% to 6/100% (days 11 – 19) and 4/80% to 5/100% (days 21 – 34). IgG detection rates were 1/25.0-2/50.0% (days 4 – 10), 4/66.6%-5/83.3% (days 11 – 19) and 5/100% (days 20 – 34) (Table 1).

**Figure 2.** IgM/IgA and IgG SARS-CoV-2 negative detection rates in asymptomatic persons (N=14)

**Discussion**

The most important current use of serology in COVID-19 diagnostics is to determine how much community transmission has occurred (seroprevalence in asymptomatic cases and mild infections)\(^\text{[10]}\). In contrast to RT-PCR, the antibodies reveal evidence of an infection any time from about a week after the infection occurred\(^\text{[11]}\). ELISA test is the most commonly used screening test for detection of novel coronaviruses. However, due to a possible cross-reactivity with other coronaviruses as well as some other viruses such as Epstein-Barr virus which induces a robust polyclonal antibody response\(^\text{[12]}\), confirmation with more specific test is required. The ELISA modular system to individually detect antibodies against SARS-CoV-2 spike protein 1, spike protein 2 and nucleocapsid seems to be more specific serological test for COVID-19. Additionally, a surrogate VNT designed to detect total neutralizing antibodies in an isotype- and species-independent manner is available which does not require a biosafety level 3 (BSL-3) laboratory\(^\text{[13]}\). However, detection of neutralizing antibodies by using a cell culture is still the ‘gold standard’ confirmatory serological test for SARS-CoV-2\(^\text{[8]}\). Since VNT requires live virus and BSL-3 laboratory, confirmatory testing is usually performed only in the reference laboratories.

In this study, the IgM/IgA (recent infection) and IgG (past infection) detection rates of six commercial tests for serological diagnosis of SARS-CoV-2 were compared. All three ELISA tests used showed generally a higher overall IgM/IgA sensitivity compared to POC tests 73.3-86.6%; 11 – 13/15 samples vs 60.0-80.0%; 9 – 12/15 samples) in patients with COVID-19, while IgG sensitivity was similar in all tests ranging

---

**INFEKTOL GLASN**

2020;40(2):50-54

Diagnosis of SARS-CoV-2 infection: preliminary results of six serology tests

Tatjana Vilibić-Čavlek et al.

**Figure 2.** IgM/IgA and IgG SARS-CoV-2 negative detection rates in asymptomatic persons (N=14)

Slika 2. Učestalost negativne detekcije IgM/IgA i IgG protutijela u asimptomatskih osoba (N=14)
from 66.6%; 10/15 samples (AMP, Euroimmun) to 73.3%; 11/15 samples (other tests). In asymptomatic persons, negative IgM/IgA detection rates varied from 85.7%; 12/14 samples (ACRO) to 100%; 14/14 samples (AMP, ENCODE, Euroimmun) and IgG from 92.8%; 13/14 samples (ACRO) to 100%; 14/14 samples (other tests).

Recently published articles and preprints deposited in MedRxiv and BiorXiv showed that SARS-CoV-2 IgM antibodies could be detected as early as three days and peaks between two and three weeks after disease onset[7-14], while IgG antibodies can be present as early as four days and peak after 17 days[6,7,15]. In a study from Singapore, 25% of the COVID-19 patients had detectable antibodies in the first week of illness, 66.7% by the second week and 100% by the third week of illness[14]. In this study IgM/IgA antibodies were detected in 1 – 2/4 (25.0%-50.0%) patients tested within 10 days, 4 – 6/6 (66.6%-100%) patients tested between 11 – 19 days and 4 – 5/5 (80%-100%) patients tested more than 20 days after disease onset. The ACRO POC test showed lower IgM detection rate in the period 20 – 34 days (4/5; 80.0%) compared to other test used (5/5; 100%), IgG detection rates were similar to IgM detection rates in the period less than 10 days (1-2/4; 25.0%-50.0%) and 11-19 days (4-5/6; 66.6%-83.3%), while all tests detected IgG antibodies 21 to 34 days after disease onset (5/5; 100%).

In a Chinese study, the positive rate for IgG reached 100% around 20 days after symptoms onset[7]. Similarly, in this study all tested POC and ELISA test detected IgG antibodies in 100% (5/5) patients tested 20 and more days after onset of symptoms. In China, three types of seroconversion were observed: synchronous seroconversion of IgG and IgM; IgM seroconverted earlier than that of IgG; IgM seroconverted later than that of IgG[13]. In patients tested in this study, majority of them had detectable both IgM and IgG antibodies at the time of testing.

One IgM positive/IgG negative sample from asymptomatic person detected by ACRO, DiaPro and Vircell was confirmed using a VNT. ENCODE and AMP POC tests did not detect IgM antibodies (false negative result). Among 14 samples from asymptomatic persons confirmed negative using a VNT, negative detection rates of IgM and/or IgA were 12/85.7% (ACRO), 13/92.8% (DiaPro, Vircell) and 14/100% (AMP, ENCODE, Euroimmun).

In conclusion, among POC tested, ENCODE test showed the highest both IgM and IgG positive detection rates in COVID-19 patients. Vircell ELISA test showed the highest IgM positive detection rate compared to other ELISA tests. In asymptomatic persons, ACRO POC showed the lowest IgM and IgG negative rates, while AMP, ENCODE and Euroimmun showed the highest negative detection rates (14/14; 100%).

This study has some limitations. Although similar with other studies, due to the small number of of samples tested, the results should be interpreted with caution. Further investigation on large number COV-ID-19 patients as well as asymptomatic persons should be performed to determine the sensitivity and specificity of serology tests in SARS-CoV-2 diagnostics.

REFERENCES

[1] World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[2] Harapan H, Ioh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health 2020;13(5):667-673.
[3] Susan Emirian E. Potential fecal transmission of SARS-CoV-2: Current evidence and implications for public health. Int J Infect Dis 2020;95:363-370.
[4] Konjevoda S, Canovic S, Pastar Z, et al. Ophthalmic manifestations of novel coronaviruses: precautionary measures and diagnostic possibilities. J Glob Health 2020;10(1):010430.
[5] Chen P, Zhang Y, Wen Y, et al. Clinical and demographic characteristics of cluster cases and sporadic cases of coronavirus disease 2019 (COVID-19) in 141 patients in the main district of Chongqing, China, between January and February 2020. Med Sci Monit 2020; 26:e923985.
[6] Lee CY, Lin RTP, Renia L, Ng LFP. Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. Front Immunol 2020;11:879.
[7] Long QX, Deng HJ, Chen J, et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. medRxiv 2020; preprint doi: 10.1102/2020.03.18.20038018.
[8] Perera RA, Mok CK, Tsang OT; et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill 2020;25(16):2000421.
[9] Vilibic-Cavlek T, Stevanovic V, Tabain I, et al. Severe acute respiratory syndrome coronavirus 2 seroprevalence among personnel in the healthcare facilities of Croatia, 2020. Rev Soc Bras Med Trop 2020; 53:e20200458.
[10] Winter AK, Hegde ST. The important role of serology for COVID-19 control. Lancet Infect Dis 2020;20(7):758-759.
[11] Petherick A. Developing antibody tests for SARS-CoV-2. Lancet 2020;395:1101-1102.
[12] Caturegli G, Materi J, Howard BM, Caturegli P. Clinical Validity of Serum Antibodies to SARS-CoV-2: A Case-Control Study. Ann Intern Med 2020;173(8):614-622.
[13] Tan CW, Chia WN, Chen Mi-C, et al. A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction. Res Square 2020; Preprint doi: 10.21203/rs.3.rs-24574/v1.
[14] Wan WY, Lim SH, Seng EH. Cross-reaction of sera from COVID-19 patients with SARS-CoV assays. medRxiv 2020; preprint doi: https://doi.org/10.1102/2020.03.17.20034454.
[15] Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020 Mar 28;ciaa344.